Altos Labs valuation, funding and investors
Altos Labs works in cellular rejuvenation programming services, based in Redwood City, United States. Founded in 2022, it has about 549 employees.
- Last round
- Series B · $800M · Jan 2022
- Valuation at last round
- $3.29B
- Headcount
- 549 · flat
- Grade
- D
- Founded
- 2022
Altos Labs valuation today
VCMC values Altos Labs at $3.4B today, with a range of $371M to $7.4B and a grade of D. The valuation starts from its last funding round, a Series B round in Jan 2022.
Valuation by date (60 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2022 | $3.3B | $2.9B – $5.7B | $4.9B (+50%) | after a round | – | unknown | B | 0% |
| 2 Jan 2022 | $3.3B | $2.9B – $5.7B | $4.9B (+50%) | after a round | – | unknown | B | 0% |
| 1 Feb 2022 | $3.4B | $2.9B – $5.7B | $4.9B (+45%) | after a round | 48 | unknown | B | 0% |
| 1 Mar 2022 | $3.5B | $2.9B – $5.7B | $4.9B (+40%) | after a round | 48 | unknown | B | 0% |
| 1 Apr 2022 | $3.6B | $2.9B – $5.7B | $4.9B (+36%) | after a round | 48 | unknown | B | 0% |
| 1 May 2022 | $3.8B | $2.9B – $5.7B | $4.9B (+31%) | after a round | 48 | unknown | B | 0% |
| 1 Jun 2022 | $3.9B | $2.9B – $5.7B | $4.9B (+27%) | after a round | 48 | unknown | B | 0% |
| 1 Jul 2022 | $4.0B | $2.9B – $5.7B | $4.9B (+23%) | after a round | 48 | unknown | B | 0% |
| 1 Aug 2022 | $4.2B | $2.9B – $5.7B | $4.9B (+19%) | after a round | 48 | unknown | B | 0% |
| 1 Sep 2022 | $4.3B | $2.9B – $5.7B | $4.9B (+15%) | after a round | 48 | unknown | B | 0% |
| 1 Oct 2022 | $4.5B | $2.9B – $5.7B | $4.9B (+11%) | after a round | 48 | unknown | B | 0% |
| 1 Nov 2022 | $4.6B | $2.9B – $5.7B | $4.9B (+7%) | after a round | 48 | unknown | B | 0% |
| 1 Dec 2022 | $4.8B | $2.9B – $5.7B | $4.9B (+4%) | after a round | 48 | unknown | B | 0% |
| 1 Jan 2023 | $4.9B | $2.9B – $5.7B | $4.9B (0%) | after a round | 48 | unknown | B | 0% |
| 1 Feb 2023 | $4.9B | $2.7B – $5.7B | $4.9B (0%) | after a round | 48 | unknown | B | 0% |
| 1 Mar 2023 | $4.9B | $2.6B – $5.7B | $4.9B (0%) | after a round | 48 | unknown | B | 0% |
| 1 Apr 2023 | $7.7B | $3.3B – $8.8B | $7.7B (0%) | after a round | 360 | growing | B | 0% |
| 1 May 2023 | $7.7B | $3.5B – $8.8B | $7.7B (0%) | after a round | 360 | growing | B | 0% |
| 1 Jun 2023 | $7.7B | $3.6B – $8.8B | $7.7B (0%) | after a round | 360 | growing | B | 0% |
| 1 Jul 2023 | $7.7B | $3.8B – $8.8B | $7.7B (0%) | after a round | 360 | growing | B | 0% |
| 1 Aug 2023 | $7.7B | $4.0B – $8.8B | $7.7B (0%) | after a round | 360 | growing | B | 0% |
| 1 Sep 2023 | $7.7B | $2.7B – $8.8B | $7.7B (0%) | after a round | 360 | unknown | B | 0% |
| 1 Oct 2023 | $8.2B | $4.0B – $9.4B | $8.2B (0%) | after a round | 470 | up | B | 0% |
| 1 Nov 2023 | $8.2B | $4.1B – $9.4B | $8.2B (0%) | after a round | 470 | up | B | 0% |
| 1 Dec 2023 | $8.2B | $4.3B – $9.4B | $8.2B (0%) | after a round | 470 | up | B | 0% |
| 1 Jan 2024 | $8.2B | $4.4B – $9.4B | $8.2B (0%) | after a round | 470 | up | B | 0% |
| 1 Feb 2024 | $8.3B | $5.1B – $9.5B | $8.3B (0%) | after a round | 510 | growing | B | 0% |
| 1 Mar 2024 | $8.3B | $5.1B – $9.6B | $8.3B (0%) | after a round | 520 | growing | B | 0% |
| 1 Apr 2024 | $8.3B | $5.2B – $9.6B | $8.3B (0%) | after a round | 520 | growing | B | 0% |
| 1 May 2024 | $8.3B | $5.2B – $9.6B | $8.3B (0%) | after a round | 520 | growing | B | 0% |
| 1 Jun 2024 | $8.3B | $5.2B – $9.6B | $8.3B (0%) | after a round | 520 | growing | B | 0% |
| 1 Jul 2024 | $8.3B | $5.2B – $9.6B | $8.3B (0%) | after a round | 520 | growing | B | 0% |
| 1 Aug 2024 | $8.4B | $5.3B – $9.7B | $8.4B (0%) | after a round | 540 | growing | B | 0% |
| 1 Sep 2024 | $8.4B | $5.3B – $9.7B | $8.4B (0%) | after a round | 540 | growing | A | 0% |
| 1 Oct 2024 | $8.4B | $5.3B – $9.7B | $8.4B (0%) | after a round | 540 | growing | A | 0% |
| 1 Nov 2024 | $8.5B | $3.2B – $9.7B | $8.2B (-4%) | after a round | 560 | up | B | 0% |
| 1 Dec 2024 | $8.5B | $3.2B – $9.7B | $8.1B (-4%) | after a round | 560 | up | B | 0% |
| 1 Jan 2025 | $8.5B | $2.1B – $9.7B | $8.1B (-4%) | after a round | 560 | up | C | 0% |
| 1 Feb 2025 | $8.4B | $2.1B – $9.7B | $8.1B (-4%) | after a round | 560 | up | C | 0% |
| 1 Mar 2025 | $8.4B | $2.0B – $9.7B | $8.0B (-4%) | after a round | 560 | up | C | 0% |
| 1 Apr 2025 | $8.4B | $1.9B – $9.6B | $8.0B (-4%) | after a round | 560 | up | C | 0% |
| 1 May 2025 | $8.3B | $1.2B – $9.5B | $7.7B (-7%) | after a round | 560 | flat | D | 0% |
| 1 Jun 2025 | $8.2B | $1.2B – $9.5B | $7.7B (-7%) | after a round | 560 | flat | D | 0% |
| 1 Jul 2025 | $8.3B | $1.7B – $9.5B | $7.8B (-6%) | after a round | 575 | up | C | 0% |
| 1 Aug 2025 | $8.2B | $1.6B – $9.5B | $7.7B (-6%) | after a round | 577 | up | C | 0% |
| 1 Sep 2025 | $8.2B | $1.6B – $9.4B | $7.6B (-6%) | after a round | 577 | up | C | 0% |
| 1 Oct 2025 | $8.0B | $950M – $9.2B | $7.4B (-8%) | after a round | 577 | flat | D | 0% |
| 1 Nov 2025 | $8.0B | $903M – $9.2B | $7.4B (-8%) | after a round | 576 | flat | D | 0% |
| 1 Dec 2025 | $7.9B | $859M – $9.1B | $7.3B (-8%) | after a round | 576 | flat | D | 0% |
| 1 Jan 2026 | $7.9B | $820M – $9.1B | $7.3B (-7%) | after a round | 585 | flat | D | 0% |
| 1 Feb 2026 | $7.9B | $779M – $9.1B | $7.3B (-7%) | after a round | 585 | flat | D | 0% |
| 1 Mar 2026 | $7.7B | $744M – $8.9B | $7.1B (-8%) | after a round | 585 | flat | D | 0% |
| 1 Apr 2026 | $7.7B | $707M – $8.8B | $7.0B (-8%) | after a round | 585 | flat | D | 0% |
| 1 May 2026 | $7.5B | $668M – $8.6B | $6.8B (-9%) | after a round | 566 | flat | D | 0% |
| 1 Jun 2026 | $6.7B | $635M – $8.3B | $6.0B (-10%) | after a round | 566 | flat | D | 5% |
| 1 Jul 2026 | $6.6B | $604M – $8.2B | $6.0B (-10%) | after a round | 566 | flat | D | 5% |
| 1 Aug 2026 | $6.6B | $574M – $8.2B | $5.9B (-10%) | after a round | 566 | flat | D | 5% |
| 1 Sep 2026 | $6.5B | $546M – $8.1B | $5.9B (-9%) | after a round | 566 | flat | D | 5% |
| 1 Oct 2026 | $4.6B | $516M – $7.5B | $4.2B (-8%) | after a round | 549 | flat | D | 23% |
| 24 Oct 2026 | $3.4B | $371M – $7.4B | $3.1B (-7%) | after a round | 549 | flat | D | 23% |
Key facts about Altos Labs
- Founded
- 2022
- Headquarters
- Redwood City, United States
- Employees
- about 549 -5% in a year
- Total raised
- $800M
- Funding rounds
- 1
- Last round
- Series B Jan 2022
Altos Labs was founded in 2022 by Hal Barron, Hans Bishop, Juan Carlos Izpisua Belmonte and Rick Klausner.
Altos Labs funding history
Altos Labs has 1 funding round on record, from Jan 2022 to Jan 2022, $800M in total. The latest disclosed valuation is $3.29B post-money (Series B, Jan 2022).
Series B 1 Jan 2022
With ARCH Venture Partners, Bezos Expedition.
$800M
$3.29B post-money
Altos Labs investors
2 investors have backed Altos Labs.
- ARCH Venture Partners
- Bezos Expedition
What Altos Labs does
Altos Labs works in biotechnology, with 14 recorded offerings and customers in biotechnology and healthcare.
Altos Labs, Inc. is an American biotechnology company engaged in cellular rejuvenation programming, drug discovery and development, and the development of life extension therapies. The company utilizes computational models and machine learning to advance its understanding of biological systems and to support the development of medicines. Altos Labs also operates the Institute of Computation, which focuses on computational models to decode biological resilience.
Description from Veridion's company data.
Products and services
- Cellular Rejuvenation Programming Services
- Induced Pluripotent Stem Cell Therapy Development
- Life Extension Therapy Research and Development
- Biological System Computational Modeling Services
- Machine Learning-Based Drug Discovery
- Biological Resilience Research and Analysis
- Scientific Collaboration Services
- Clinical-Driven Therapeutic Development
- Cell Therapy Development Services
- Biological Data Interpretation Services
- Transformative Medicine Development
- Cell Health Restoration Services
- Disease and Injury Countermeasure Services
- Disability Prevention Therapeutic Development
Markets
- Biotechnology
- Healthcare
Technology
- Computational Models for Biological Resilience
- Machine Learning for Biological Systems
- Induced Pluripotent Stem Cells
Business model
- Business-to-Business
- Service Provider
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Altos Labs
What is Altos Labs worth?
Valuation $3.4B (range $371M to $7.4B), as of 24 Oct 2026. The last disclosed valuation was $3.29B (Series B, Jan 2022).
Has Altos Labs raised money?
Altos Labs has 1 funding round on record, from Jan 2022 to Jan 2022, $800M in total. The latest disclosed valuation is $3.29B post-money (Series B, Jan 2022).
Who has invested in Altos Labs?
ARCH Venture Partners and Bezos Expedition.
How many people work at Altos Labs?
About 549, down 5% over the last year. Headcount grew from 48 in Feb 2022 to 549 in Sep 2026.
What does Altos Labs do?
Altos Labs works in biotechnology, with 14 recorded offerings and customers in biotechnology and healthcare. Its main offerings are cellular rejuvenation programming services, induced pluripotent stem cell therapy development and life extension therapy research and development.
When was Altos Labs founded, and where is it based?
Altos Labs was founded in 2022 and is based in Redwood City, United States. It has about 549 employees, down 5% over the last year.